This is a real product in a real market, but shareholder capture depends on turning added
Gen-3 supply into recurring contracts faster than launch delays, financing needs, and policy friction consume the upside. The biggest risks are not technical irrelevance; they are capital structure, external launch cadence, government timing, and whether BlackSky owns enough of the workflow to keep pricing power.